Open AccessMedication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study
Author(s) -
Marisol Samartín-Ucha,
José M. Pego-Reigosa,
Miriam Álvarez-Payero,
Alicia Martín-Vila,
Guadalupe Piñeiro-Corrales,
Maria del Pilar Rodríguez-Rodríguez,
Rafael Benito Melero-González,
Francisco José Maceiras-Pan,
Cristina Martínez-Reglero,
Noemi Mrtinez-Lopez de Castro
Publication year - 2020
Publication title -
european journal of hospital pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.313
H-Index - 14
eISSN - 2047-9964
pISSN - 2047-9956
DOI - 10.1136/ejhpharm-2019-002133
Subject(s) - medicine , discontinuation , ankylosing spondylitis , psoriatic arthritis , persistence (discontinuity) , rheumatoid arthritis , arthritis , retrospective cohort study , cohort , cohort study , surgery , geotechnical engineering , engineering
Medication persistence, defined as the duration of time from its initiation to its discontinuation, is a surrogate for treatment effectiveness. The aim of the study was to evaluate persistence and causes of biological therapy (BT) suspension in patients with chronic inflammatory arthropathies: rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.